Low-density lipoprotein cholesterol: How low can we go?

Daniel P. Sherbet, Puja Garg, Emmanouil S. Brilakis, Subhash Banerjee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Elevated low-density lipoprotein cholesterol (LDL-C) is an established cause of cardiovascular disease and subsequent adverse events. The efficacy and safety of lowering plasma LDL-C to reduce the risk of coronary heart disease (CHD) and secondary event rates are now well established. What has not been established, however, is a plasma LDL-C lower threshold level of safety and efficacy. Here we review intensive plasma LDL-C-lowering with statins and argue that even further reductions of plasma LDL-C than current guideline targets is likely to safely reduce cardiovascular event rates. We discuss how to achieve very low levels of plasma LDL-C using both traditional and novel LDL-lowering therapies.

Original languageEnglish (US)
Pages (from-to)225-232
Number of pages8
JournalAmerican Journal of Cardiovascular Drugs
Volume13
Issue number4
DOIs
StatePublished - Aug 2013

Fingerprint

LDL Cholesterol
Safety
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Disease
Cardiovascular Diseases
Guidelines

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Low-density lipoprotein cholesterol : How low can we go? / Sherbet, Daniel P.; Garg, Puja; Brilakis, Emmanouil S.; Banerjee, Subhash.

In: American Journal of Cardiovascular Drugs, Vol. 13, No. 4, 08.2013, p. 225-232.

Research output: Contribution to journalArticle

@article{efbe5fdb686246bb90f44a4a8ecf7303,
title = "Low-density lipoprotein cholesterol: How low can we go?",
abstract = "Elevated low-density lipoprotein cholesterol (LDL-C) is an established cause of cardiovascular disease and subsequent adverse events. The efficacy and safety of lowering plasma LDL-C to reduce the risk of coronary heart disease (CHD) and secondary event rates are now well established. What has not been established, however, is a plasma LDL-C lower threshold level of safety and efficacy. Here we review intensive plasma LDL-C-lowering with statins and argue that even further reductions of plasma LDL-C than current guideline targets is likely to safely reduce cardiovascular event rates. We discuss how to achieve very low levels of plasma LDL-C using both traditional and novel LDL-lowering therapies.",
author = "Sherbet, {Daniel P.} and Puja Garg and Brilakis, {Emmanouil S.} and Subhash Banerjee",
year = "2013",
month = "8",
doi = "10.1007/s40256-013-0013-8",
language = "English (US)",
volume = "13",
pages = "225--232",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Low-density lipoprotein cholesterol

T2 - How low can we go?

AU - Sherbet, Daniel P.

AU - Garg, Puja

AU - Brilakis, Emmanouil S.

AU - Banerjee, Subhash

PY - 2013/8

Y1 - 2013/8

N2 - Elevated low-density lipoprotein cholesterol (LDL-C) is an established cause of cardiovascular disease and subsequent adverse events. The efficacy and safety of lowering plasma LDL-C to reduce the risk of coronary heart disease (CHD) and secondary event rates are now well established. What has not been established, however, is a plasma LDL-C lower threshold level of safety and efficacy. Here we review intensive plasma LDL-C-lowering with statins and argue that even further reductions of plasma LDL-C than current guideline targets is likely to safely reduce cardiovascular event rates. We discuss how to achieve very low levels of plasma LDL-C using both traditional and novel LDL-lowering therapies.

AB - Elevated low-density lipoprotein cholesterol (LDL-C) is an established cause of cardiovascular disease and subsequent adverse events. The efficacy and safety of lowering plasma LDL-C to reduce the risk of coronary heart disease (CHD) and secondary event rates are now well established. What has not been established, however, is a plasma LDL-C lower threshold level of safety and efficacy. Here we review intensive plasma LDL-C-lowering with statins and argue that even further reductions of plasma LDL-C than current guideline targets is likely to safely reduce cardiovascular event rates. We discuss how to achieve very low levels of plasma LDL-C using both traditional and novel LDL-lowering therapies.

UR - http://www.scopus.com/inward/record.url?scp=84880892760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880892760&partnerID=8YFLogxK

U2 - 10.1007/s40256-013-0013-8

DO - 10.1007/s40256-013-0013-8

M3 - Article

C2 - 23609530

AN - SCOPUS:84880892760

VL - 13

SP - 225

EP - 232

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 4

ER -